Last reviewed · How we verify
insulin glargine + preprandial lispro insulin
At a glance
| Generic name | insulin glargine + preprandial lispro insulin |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes (PHASE3)
- A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus (PHASE3)
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (PHASE4)
- A Study of LY900014 in Participants With Type 1 Diabetes (PHASE3)
- Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery (PHASE4)
- Linagliptin Inpatient Trial (PHASE4)
- Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes (PHASE4)
- Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: